fibromyalgia

The firm's recent funding round will support its CLIA-certified laboratory that opened last year and the launch of its first RNA-based diagnostic test.

The company is aiming to uncover the cause of fibromyalgia and to identify new disease-specific genetic biomarkers.

IQuity's current tests analyze gene expression patterns detected in mRNA, but the firm is also exploring the diagnostic potential of long non-coding RNAs.

Biotech startup EpicGenetics last month launched its FM/A protein biomarker test for fibromyalgia with the aim of providing an objective method of diagnosing what has traditionally been a difficult to pin down disease.

Catalyst hopes to develop treatments for addiction and epilepsy based on the compounds, which may be more potent and induce fewer side effects than a related compound that Catalyst previously licensed from Brookhaven National Laboratory and is currently shepherding through clinical trials.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.